Journal
CLINICAL LUNG CANCER
Volume 23, Issue 6, Pages 542-546Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2022.05.011
Keywords
Pembrolizumab; Sarcoidosis; Lung cancer
Categories
Ask authors/readers for more resources
Immune checkpoint inhibitor therapy has revolutionized the treatment approach for various cancers, including non-small cell lung cancer. However, this therapy can give rise to a wide range of immune-related adverse effects, necessitating prompt identification and management. As the use of immune checkpoint inhibitors becomes more prevalent, rare immune-related adverse effects are increasingly being recognized. This case report presents a patient with advanced non-small cell lung cancer who developed pembrolizumab-associated sarcoidosis involving multiple organs. A multidisciplinary approach to management led to timely diagnosis and treatment, resulting in symptom improvement. This case raises awareness about the rare side effect of sarcoidosis associated with pembrolizumab.
Immune checkpoint inhibitor (ICI) therapy has reshaped the treatment landscape in many cancers including non-small cell lung cancer (NSCLC). ICI-therapy can lead to a diverse array of immune-related adverse effects (irAEs), and prompt recognition and management are key to successful treatment. With wide-spread use of ICI therapy in clinical practice, rare irAEs are being increasingly recognized. This report documents a patient with advanced NSCLC who developed pembrolizumab-associated sarcoidosis with multiorgan involvement. Multidisciplinary management led to timely diagnosis and treatment, leading to improvement in symptoms. This case raises awareness of sarcoidosis as a rare side effect of pembrolizumab. (C) 2022 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available